Evaluation of the Cepheid Xpert GBS Assay for Rapid Detection of Group B Streptococci in Amniotic Fluids from Pregnant Women with Premature Rupture of Membranes

Nadege Bourgeois-Nicolaos, Anne-Gael Cordier, Christelle Guillet-Caruba, François Casanova, Alexandra Benachi and Florence Doucet-Populaire


Updated information and services can be found at: http://jcm.asm.org/content/51/4/1305

**REFERENCES**

These include:

This article cites 9 articles, 3 of which can be accessed free at: http://jcm.asm.org/content/51/4/1305#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Evaluation of the Cepheid Xpert GBS Assay for Rapid Detection of Group B Streptococci in Amniotic Fluids from Pregnant Women with Premature Rupture of Membranes

Nadège Bourgeois-Nicolaos, Anne-Gael Cordier, Christelle Guillet-Caruba, François Casanova, Alexandra Benachi, Florence Doucet-Populaire

Service de Bactériologie-Hygiène, Hôpital Antoine Béclère, AP-HP, Université Paris Sud, Clamart, France; Service de Gynécologie-Obstétrique et Médécine de la Reproduction, Hôpital Antoine-Béclère, AP-HP, Université Paris Sud, Clamart, France; Université Paris Sud, EA 4043 USC INRA, Chatenay-Malabry, France

The Xpert GBS real-time PCR assay for the detection of group B streptococci (GBS) in antepartum screening samples was evaluated on amniotic fluid samples collected from 139 women with premature rupture of membrane at term. When any intrapartum positive result from the Xpert GBS or culture was considered a true positive, the sensitivities of the Xpert GBS and culture were 92.3% and 84.6%, respectively. This assay could enhance exact identification of candidates for intrapartum antibiotic prophylaxis.

Streptococcus agalactiae, also known as group B streptococcus (GBS), is the leading infectious cause of neonatal morbidity and mortality. Maternal GBS colonization is one of the most important risk factors for early onset GBS disease (EO-GBSD). Mother-child transmission can occur during membrane rupture or delivery. The reported rate of GBS vaginal colonization among pregnant women ranges from 4% to 36% in Europe (1). The risk of EO-GBSD increases in cases of preterm delivery, maternal fever, and premature rupture of membrane (PROM) more than 12 h before delivery. Intrapartum antibiotic prophylaxis (IAP) reduces significantly the incidence of EO-GBSD (2). It is still debated whether this IAP will favor colonization by antibiotic-resistant bacteria (3, 4). In France, the strategy to identify women for targeted IAP is based on universal antenatal screening with vaginal culture at 35 to 37 weeks gestation (5). GBS culture remains the gold standard for the detection of GBS colonization. However, its turnaround time (TAT) varies from 18 to 72 h, which makes it not adapted for intrapartum screening.

Term PROM is defined as the spontaneous rupture of membranes more than 12 h at term before the onset of regular uterine contractions. PROM at term affects 8 to 10% of pregnant women (6). When PROM is confirmed, active management with labor induction or expectant management is possible. One criterion for expectant management is GBS-negative status while pregnant women with GBS-positive term PROM should be offered antibiotic prophylaxis and induction of labor (6). However, it has been well documented that results of antepartum GBS screening culture do not always accurately predict intrapartum GBS status (7, 8). A nucleic acid amplification test (NAAT) may be able to identify women who are positive at the time of delivery. The Xpert GBS (Cepheid) has shown to be an accurate and easy-to-use PCR for the detection of GBS DNA from vaginal or rectal specimens (8, 9). With Xpert GBS intrapartum screening, significant decreases in neonatal infections and the length of stay (LOS) were demonstrated (47% fewer hospitalization days in neonatology/90% fewer days in the intensive care unit [ICU]) (10).

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor. 

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor. 

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor. 

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.

The objective of our study was to validate the Xpert GBS assay directly on amniotic fluids collected from pregnant women with rupture of membranes at term gestation before the onset of labor.
extracted the DNA, and performed a sequencing analysis. A faint band appeared on the gel after PCR with sequencing primers, confirming this sample was GBS positive. After quantification by culture of the initial amniotic fluid, we showed only $10^3$ CFU/ml; this very low quantity is certainly the explanation of this result. We also obtained two samples that were positive by PCR, with a cycle threshold of 39.3, and negative by culture. When any intrapartum positive result from the Xpert GBS assay or culture was considered a true positive of GBS colonization, the sensitivities of the Xpert GBS assay and standard culture were 92.3% (12/13) and 84.6% (11/13), respectively.

Of the 139 enrolled women, 133 underwent GBS culture screening at 35 to 37 weeks gestation (Table 2). Among the 6 women without available culture status, 5 were negative by PCR and 1 was positive by PCR. The antenatal GBS colonization rate by culture and the intrapartum GBS colonization rate by PCR were 8.3% (11/139). However, 54.6% (6/11) of those women found to be GBS positive in amniotic fluid by the Xpert GBS assay did not have GBS detected in antepartum culture. No GBS invasive disease in mothers and newborns studied were observed during the study period compared to the previous year, May 2010 to May 2011, in which we observed 1 bacteremia among the women.

To the best of our knowledge, this is the first validation of the Xpert GBS assay in amniotic fluids. In our study, the results of the Xpert GBS assay in amniotic fluids. In our study, the results of the NAAT intrapartum and antepartum culture were discordant in 9% of women overall. The PCR assay has allowed withholding IAP in half of the women with an antepartum-positive GBS screening. At this time, the Xpert GBS assay is the only method available for identification of PROM women at risk that allows the clinicians to prescribe the IAP and to potentially avoid the delivery of a GBS-colonized neonate from women who would otherwise not be determined to be at risk.

In summary, the Xpert GBS assay is a rapid and accurate method for GBS detection in amniotic fluids. This tool could enhance the exact identification of candidates for IAP and be helpful for management of women with PROM.

TABLE 1 Detection of GBS in 139 amniotic fluids by culture and Xpert GBS assay

<table>
<thead>
<tr>
<th>GBS culture</th>
<th>Positive</th>
<th>Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>10</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
<td>126</td>
<td>128</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>127</td>
<td>139</td>
</tr>
</tbody>
</table>

extracted the DNA, and performed a sequencing analysis. A faint band appeared on the gel after PCR with sequencing primers, confirming this sample was GBS positive. After quantification by culture of the initial amniotic fluid, we showed only $10^3$ CFU/ml; this very low quantity is certainly the explanation of this result. We also obtained two samples that were positive by PCR, with a cycle threshold of 39.3, and negative by culture. When any intrapartum positive result from the Xpert GBS assay or culture was considered a true positive of GBS colonization, the sensitivities of the Xpert GBS assay and standard culture were 92.3% (12/13) and 84.6% (11/13), respectively.

Of the 139 enrolled women, 133 underwent GBS culture screening at 35 to 37 weeks gestation (Table 2). Among the 6 women without available culture status, 5 were negative by PCR and 1 was positive by PCR. The antenatal GBS colonization rate by culture and the intrapartum GBS colonization rate by PCR were 8.3% (11/139). However, 54.6% (6/11) of those women found to be GBS positive in amniotic fluid by the Xpert GBS assay did not have GBS detected in antepartum culture. No GBS invasive disease in mothers and newborns studied were observed during the study period compared to the previous year, May 2010 to May 2011, in which we observed 1 bacteremia among the women.

To the best of our knowledge, this is the first validation of the Xpert GBS assay in amniotic fluids. In our study, the results of the

TABLE 2 Comparison of Xpert GBS assay and GBS culture on amniotic fluid samples versus GBS culture screening at 35 to 37 weeks gestation in women with PROM ≥37 weeks gestation

<table>
<thead>
<tr>
<th>Documented results of antepartum GBS culture</th>
<th>PCR (+)</th>
<th>PCR (−)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR (+) culture+</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>PCR (+) culture−</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PCR (−) culture+</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PCR (−) culture−</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>2</td>
<td>12</td>
</tr>
</tbody>
</table>

In summary, the Xpert GBS assay is a rapid and accurate method for GBS detection in amniotic fluids. This tool could enhance the exact identification of candidates for IAP and be helpful for management of women with PROM.

TABLE 2 Comparison of Xpert GBS assay and GBS culture on amniotic fluid samples versus GBS culture screening at 35 to 37 weeks gestation in women with PROM ≥37 weeks gestation

<table>
<thead>
<tr>
<th>Documented results of antepartum GBS culture</th>
<th>PCR (+)</th>
<th>PCR (−)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR (+) culture+</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>PCR (+) culture−</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PCR (−) culture+</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PCR (−) culture−</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>2</td>
<td>12</td>
</tr>
</tbody>
</table>

In summary, the Xpert GBS assay is a rapid and accurate method for GBS detection in amniotic fluids. This tool could enhance the exact identification of candidates for IAP and be helpful for management of women with PROM.

ACKNOWLEDGMENT

We declare that we have no conflicts of interest.

REFERENCES